Aurisco Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	616.59	769.44	545.84	391.74	444.61	564.1
Trading Asset Securities	424.24	299.83	-	-	-	-
Cash & Short-Term Investments	1,041	1,069	545.84	391.74	444.61	564.1
Cash Growth	-7.70%	95.89%	39.34%	-11.89%	-21.18%	112.82%
Accounts Receivable	398.39	350.87	290.78	222.11	140.72	142.85
Other Receivables	1.89	4.23	8.31	3.9	6.19	3.91
Receivables	400.28	355.11	299.09	226.01	146.91	146.76
Inventory	622.98	589.72	509.8	444.94	326.8	237.79
Prepaid Expenses	-	-	-	0.17	-	-
Other Current Assets	18.96	32.7	11.31	25.5	21.48	29.12
Total Current Assets	2,083	2,047	1,366	1,088	939.8	977.76
Property, Plant & Equipment	1,631	1,497	878.33	674.18	593.26	490.35
Long-Term Investments	145.07	133.47	79.3	55.3	15.3	0.3
Other Intangible Assets	158.65	161.46	121.4	122.71	40.42	41.94
Long-Term Deferred Tax Assets	20.29	15.78	14.29	15.24	8.56	6.3
Long-Term Deferred Charges	5.67	5.32	6.91	11.37	-	-
Other Long-Term Assets	24.3	17.41	108.35	68.14	124.09	16.56
Total Assets	4,068	3,877	2,575	2,035	1,721	1,533
Accounts Payable	299.56	297.39	242.53	102.43	128.2	97.05
Accrued Expenses	50.08	121.64	92.89	51.95	40.89	23.13
Short-Term Debt	40.03	20.02	40.04	30	-	-
Current Portion of Long-Term Debt	-	-	-	1.3	-	-
Current Portion of Leases	15.97	5.64	5.14	4.93	4.06	-
Current Income Taxes Payable	24.47	25	16.64	12.85	8.61	16.94
Current Unearned Revenue	4.43	6.6	22.25	0.98	8.96	1.93
Other Current Liabilities	49.82	55.74	81.53	117.75	2.36	2.57
Total Current Liabilities	484.35	532.04	501.02	322.17	193.08	141.61
Long-Term Debt	918.81	907.09	60.46	4.22	-	-
Long-Term Leases	16.35	15.1	11.24	12.23	13.91	-
Long-Term Unearned Revenue	106.07	91.57	34.02	7.69	4.53	4.14
Long-Term Deferred Tax Liabilities	1.06	0.1	0.28	4.81	1.92	2.23
Total Liabilities	1,527	1,546	607.03	351.13	213.44	147.98
Common Stock	406.2	406.2	406.2	406.2	401	401
Additional Paid-In Capital	613.65	606.5	584.93	553.36	491.73	489.87
Retained Earnings	1,477	1,241	975.92	751.49	592.71	472.12
Treasury Stock	-58.47	-22.86	-45.72	-57.15	-	-
Comprehensive Income & Other	102.31	100.34	46.25	22.28	20.8	22.24
Total Common Equity	2,541	2,332	1,968	1,676	1,506	1,385
Minority Interest	-	-	-	7.99	1.75	-
Shareholders' Equity	2,541	2,332	1,968	1,684	1,508	1,385
Total Liabilities & Equity	4,068	3,877	2,575	2,035	1,721	1,533
Total Debt	991.16	947.85	116.88	52.69	17.97	-
Net Cash (Debt)	49.67	121.42	428.95	339.05	426.64	564.1
Net Cash Growth	-81.01%	-71.69%	26.52%	-20.53%	-24.37%	112.82%
Net Cash Per Share	0.12	0.30	1.05	0.84	1.06	1.51
Filing Date Shares Outstanding	406.2	406.2	406.2	406.2	401	401
Total Common Shares Outstanding	406.2	406.2	406.2	406.2	401	401
Working Capital	1,599	1,515	865.02	766.19	746.72	836.15
Book Value Per Share	6.26	5.74	4.84	4.13	3.76	3.45
Tangible Book Value	2,383	2,170	1,846	1,553	1,466	1,343
Tangible Book Value Per Share	5.87	5.34	4.55	3.82	3.66	3.35
Buildings	-	291.81	291.85	289.74	283.37	277.72
Machinery	-	735.79	640.39	587.27	485.03	316.43
Construction In Progress	-	869.74	280.64	79.93	47.83	90.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.